Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research CNS/Neurology Market Research

Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)

Best Price Guarantee Length Publisher Published Date SKU
from $8,000 285 Pages Kalorama Information April, 2025 KLI19997577
Best Price Guarantee
Price from $8,000
Length 285 Pages
Publisher Kalorama Information
Published Date April, 2025
SKU KLI19997577

Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)

The Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030) report by Kalorama Information explores the transformative potential of cell and gene therapies in modern medicine. These therapies offer groundbreaking treatments by addressing genetic causes of diseases and modulating the immune system. The report highlights the surge in new therapies and a promising pipeline, with significant clinical trial activity across various therapeutic areas, including oncology and cardiology.

This comprehensive report segments the market by therapeutic areas, providing detailed market estimates, forecasts, and insights into the competitive landscape. It covers global developments in cell, gene, and RNA therapy markets, focusing on key products, research trends, market breakdowns, regional revenues, and competitor analysis.

Key therapeutic areas covered include:

  • Oncology
  • Neurology
  • Musculoskeletal
  • Dermatology
  • Cardiology/Non-oncology blood
  • Other
The report excludes RNA therapies for COVID-19 and mRNA vaccines for infectious diseases, focusing instead on broader gene therapy applications. It also omits cord blood products, considering their classification as transplants.

Methodologically, the report combines primary and secondary research, including interviews with industry participants and comprehensive literature reviews. It provides market highlights, forecasts, and competitive analyses, discussing market indicators, trends, and barriers. Given the nascent stage of gene therapies, forecasts are based on limited precedents, with market size estimates provided for 2024 and projections through 2030.

This report serves as a crucial resource for understanding the evolving landscape of cell and gene therapies, offering valuable insights for stakeholders in the healthcare and biotechnology sectors.

Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030) is also the companion to another 2025 Kalorama Information report, Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition) , which provides an unparalleled deep dive into the CGT market’s financial ecosystem, covers financing, funding, partnering, M&A, tech transfers, IPOs/SPACs, and other deals.


  • Executive Summary
    • Overview
    • Scope and Methodology
    • Market Overview and Potential
      • Table Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Global Cell and Gene Therapy Market, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Global Share of Cell and Gene Therapy Market, by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Global Share of Cell and Gene Therapy Market, by Product Segment, 2029 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
  • Introduction to Cell and Gene Therapy
    • Introduction
      • Table Total Numbers of Approved Cell, Gene, &RNA Therapies, by Type, 2022-2024, Global (count, %)
      • Table Share of Total Global Numbers of Approved Cell, Gene, &RNA Therapies, by Type, January 2025 (%)
    • Cell Therapy
      • CAR T
      • Stem Cells
      • Adult Stem Cells
      • Human Embryonic Stem Cells
        • Table Adult vs. Embryonic Stem Cells
    • Gene Therapy
      • Table Somatic vs. Germ Line Gene Therapy
      • Viral Vector System and New Developments
        • Table Selected Examples of Viruses in Gene Therapy
        • Table Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)
      • Non-viral Systems for Transporting Genes
      • Gene Editing
    • Cell and Gene Therapy: Characteristics
      • Table Cell Therapy vs Gene Therapy
    • Staffing
    • Manufacturing Process for CAR-T
      • Leukapheresis
      • Activation
      • Transduction
      • Expansion
    • Cell and Gene Therapy Manufacturing Processes
      • Table Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
      • Table Manufacturing Process Time for Select Autologous Cell and Gene Therapies [current and discontinued therapies]
    • Cost
    • Reimbursement
    • Logistics
    • Mergers and Acquisitions
      • Table Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
    • Deals, Agreements, and Collaborations
    • Regulatory Developments
      • Fast Track
      • Orphan Drug
      • Breakthrough Therapy
      • Accelerated Approval
      • Priority Review
        • Table Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country
      • Gene Therapy Approval Process
    • Pipeline, Development Overview
    • Pipeline, Development Progress
      • Table Global Cell, Gene, &RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), 2022-2024 (Count, %)
      • Table Global Cell, Gene, &RNA Therapy Development Progress (pre-clinical through phase III), as of Q4 2024
      • Table Global Gene Therapy Pipeline, by Phase, 2022-2024 (count, %)
      • Table Global Gene Therapy Pipeline Shares by Phase, Q4 2024 (%)
    • Pipeline by Condition and Therapeutic Area
      • Table Global Cell, Gene, &RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
      • Table Global Gene Therapy Pipeline Shares, by Therapeutic Area, Q4 2024 (%) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
      • Table Global Cell, Gene, &RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other]
      • Table Global Cell, Gene, &RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other]
      • Table Global Cell, Gene, &RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease, Share Q4 2024 (%) [Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa]
      • Table Global Non-GM Cell Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, NA/Unspecified]
      • Table Global Non-GM Cell Therapy Pipeline, by Condition/Disease, 2022-2024 (count, %) [Alzheimer's disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson's disease; Respiratory distress syndrome, acute; Spinal cord injury]
      • Table Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin's; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne's muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington's disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia]
      • Table Global RNA Therapy Pipeline, by Therapeutic Area, 2022-2024 (count, %) [Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary (including sex hormones), Hormonal (excluding sex hormones), Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous]
      • Table Global RNA Therapy Pipeline, by Rare Disease Targeted, 2022-2024 (count, %) [Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal; Dystrophy, Duchenne's muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington's disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute]
    • Phase III Development
      • Table Phase III Development - Cell and Gene Therapies, Select Projects
    • End Users
      • Hospitals
      • Research Institutes
      • Wound Care Centers
      • Cancer Centers
  • Cell and Gene Therapy Markets in Oncology
    • Overview
      • Biochemistry of Cancer Cells
    • Causes of Cancer Growth
      • Environmental Factors, DNA, RNA
        • Table Virus Association with Human Cancer
      • Cellular Oncogenes
      • Tumor Suppressor Genes
    • Global Cancer Burden
      • Table Estimated Number of New Cancer Cases, Both Sexes, Age 0-85+, All Cancers, 2020 to 2040
      • Table Incidence of Cancer, by Type, 2020 [Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid]
      • Table Worldwide Distribution of Cancer Incidence, by Type, 2020 [Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers]
    • Market Outlook
      • Table Cell, Gene, &RNA Therapy Markets in Oncology, 2024-2030 ($ million)
      • Table Cell, Gene, &RNA Therapy Markets in Oncology, 2024-2030 ($ million)
    • Principal Products
      • Abecma
      • APCeden
      • Aucatzyl
      • Breyanzi
      • Carvykti
      • CreaVax-RCC
      • Delytact
      • Gendicine
      • Imlygic
      • Immuncell-LC
      • Kymriah
      • Provenge
      • Relma-cel
      • Rytelo
      • Tecartus
      • Tecelra
      • Yescarta
      • Zevor-cel
        • Table Cell and Gene Therapy in Oncology
    • Trends in Research and Development
      • Phase III Development
        • Table Select Oncology Phase III Cell, Gene, &RNA Therapy Developments, through March 2025
    • Market Breakdown of Cell and Gene Therapies
      • Table Oncology Cell and Gene Therapy Markets, by Product Type, Estimated Sales 2024 and Projected 2030 Sales ($ million) [CAR-T, Cell Immunotherapy, Gene/Oligo/Conjugate Therapy, Other Cell]
      • Table Oncology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [CAR-T, Cell Immunotherapy, Gene Therapy]
      • Oncology Cell and Gene Therapy Market by Cancer Type
        • Table Oncology Cell, Gene, &RNA Therapy Market, by Cancer Type, Estimated 2024 and Projected 2030 Sales ($ million) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Undefined Blood Cancer, Other Cancers]
        • Table Oncology Cell, Gene, &RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
        • Table Oncology Cell, Gene, &RNA Therapy Market, by General Indication, 2024 (%) [Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers]
    • Regional Market Summary
      • Table Oncology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
      • Table Oncology Cell and Gene Therapy Market, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
      • Table Oncology Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
    • Competitor Summary
      • Table Oncology Cell, Gene, &RNA Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
      • Table Oncology Cell, Gene, &RNA Therapy Competitor Sales, Estimated 2024 ($ million) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
      • Table Oncology Cell, Gene, &RNA Therapy Competitor Market Share, Estimated 2024 (%) [BMS, Dendreon, Gilead/Kite, Janssen, Novartis, Others]
  • Cell and Gene Therapy Markets in Neurological-Related Disorders
    • Overview
    • Market Outlook
      • Table Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
      • Table Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2024-2030 ($ million)
    • Principal Products
      • Amvuttra
      • Libmeldy/ Lenmeldy
      • NeuroNata-R
      • Onpattro
      • SKYSONA
      • Spinraza
      • Stemirac
      • Upstaza
      • Wainua
      • Zolgensma
        • Table Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders
    • Trends in Research and Development
      • Phase III Development
        • Table Select Neurological Phase III Cell and Gene Therapy Developments, through January 2025
    • Market Breakdown of Cell and Gene Therapies
      • Table Neurological Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
      • Table Neurological Conditions Cell, Gene, &RNA Therapy Market Distribution, by Product Type, 2024 (%) [Cell Therapy, Gene Therapy, RNA/Antisense Therapy]
    • Regional Market Summary
      • Table Neurological Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
      • Table Neurological Conditions Cell, Gene, &RNA Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
    • Competitor Summary
      • Table Neurological Conditions Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million, %) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]
      • Table Neurological Conditions Cell, Gene, &RNA Therapy Market Shares, by Company, Estimated 2024 ($ million) [Alnylam Pharmaceuticals, Biogen, Novartis, Others]
  • Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
    • Overview
    • Market Outlook
      • Table Cell, Gene, &RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
      • Table Cell, Gene, &RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2024-2030 ($ million)
    • Principal Products
      • AlloStem
      • Amondys
      • BIO4
      • Carticel
      • Cartiform
      • CartiLife
      • Cartistem
      • Chondron
      • Elevidys
      • Exondys
      • JACC
      • MACI
      • Ortho-ACI and Ortho-ATI
      • Ossron
      • Osteocel and Osteoplus
      • Spherox
      • Trinity Elite and Trinity Evolution
      • Vyondys
        • Table Cell and Gene Therapies in Musculoskeletal Diseases and Disorders
    • Trends in Research and Development
      • Phase III Development
        • Table Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2025
    • Market Breakdown of Cell and Gene Therapies
      • Table Musculoskeletal Cell, Gene, &RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million)
      • Musculoskeletal Cell and Gene Therapy Market by Indication
        • Table Musculoskeletal Cell, Gene, &RNA Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others (Tendon Damage, Osteoarthritis)]
        • Table Musculoskeletal Cell, Gene, &RNA Therapy Market, by General Indication, Estimated 2024 (%) [Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others (Tendon Damage, Osteoarthritis)]
    • Regional Market Summary
      • Table Musculoskeletal Cell, Gene, &RNA Therapy Market, by Country/Region, Estimated 2024 (%) [APAC, Europe, United States, ROW]
      • Table Musculoskeletal Cell, Gene, &RNA Therapy Market, by Country/Region, 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
      • Table Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, United States, ROW]
    • Competitor Summary
      • Table Musculoskeletal Cell, Gene, &RNA Therapy Competitor Market Share, Reported and Estimated 2024 ($ million) [Sarepta, Vericel, Other Companies]
      • Table Musculoskeletal Cell, Gene, &RNA Therapy Market Shares, by Company, Estimated 2024 (%) [Sarepta, Vericel, Other Companies]
  • Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
    • Overview
      • Cardiovascular Disease
      • Selected Blood Disorders
    • Market Outlook
      • Table Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
      • Table Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2024-2030 ($ million)
    • Principal Products
      • Collategene
      • Hearticellgram
      • HeartSheet
      • Leqvio
      • Neovasculgen
      • Stempeucel
      • Zynteglo
        • Table Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
      • Phase III Development
        • Table Select Cardiovascular and Blood Disorder in Phase III Cell and Gene Therapy Developments, through January 2025
    • Market Breakdown of Cell, Gene, and RNA Therapies
      • Table Cardiovascular and Blood Disorders Cell, Gene, &RNA Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies]
      • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
        • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication, Estimated 2024 and Projected 2030 Sales ($ million) [Blood, Cardiac, Hypercholesterolemia, Vascular]
    • Regional Market Summary
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
      • Table Cardiovascular and Blood Disorders Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [APAC, Europe, North America, ROW]
    • Competitor Summary
  • Cell and Gene Therapy Markets in Dermatology
    • Overview
      • Table Wound Prevalence, by Type [Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns]
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
      • Table Cell and Gene Therapy Markets in Dermatology, 2024-2030 ($ million)
    • Principal Products
      • Adipocel
      • Apligraf
      • CureSkin
      • Dermagraft
      • Epicel
      • Grafix
      • Holoderm
      • Kaloderm
      • KeraHeal/KeraHeal-Allo
      • LaViv
      • Orcel
      • Quencell
      • RECELL
      • Rosmir
      • Stempeutics/Cutisera
      • StrataGraft
      • Stravix
      • TransCyte
      • Vyjuvek
        • Table Cell and Gene Therapy in Dermatological Diseases and Disorders
    • Trends in Research and Development
      • Phase III Development
        • Table Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2025
    • Market Breakdown of Cell and Gene Therapies
      • Table Dermatology Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
      • Table Dermatology Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy]
      • Dermatology Cell and Gene Therapy Market by Indication
    • Regional Market Summary
      • Table Dermatology Cell and Gene Therapy Market, by Country/Region, Estimated 2024 & Projected 2030 Sales ($ million) [APAC, Europe, North America, ROW]
      • Table Dermatology Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [APAC, Europe, North America, ROW]
      • Table Dermatology Cell and Gene Therapy Market Share, by Geographic Region, 2024 (%) [APAC, Europe, North America, ROW]
    • Competitor Summary
      • Table Dermatology Cell and Gene Therapy Competitor Sales and Market Share, Reported and Estimated 2024 ($ million) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]
      • Table Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2024 (%) [Krystal Biotech, Organogenesis, Smith & Nephew (Osiris), Vericel, Other]
  • Cell and Gene Therapy Markets in Other Conditions
    • Overview
    • Market Outlook
      • Table Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
      • Table Cell and Gene Therapy Markets in Other Conditions, 2024-2030 ($ million)
    • Principal Products
      • Alofisel
      • Cupistem
      • Givlaari
      • Glybera
      • Holoclar
      • Luxturna
      • Oxlumo
      • Rethymic
      • Ryoncil/ Prochymal/ Temcell
      • Tryngolza
        • Table Cell and Gene Therapy in Other Diseases and Disorders
    • Trends in Research and Development
    • Market Breakdown of Cell and Gene Therapies
      • Table Other Conditions Cell and Gene Therapy Markets, by Product Type, Estimated 2024 and Projected 2030 Sales ($ million) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
      • Table Other Conditions Cell and Gene Therapy Market Distribution, by Product Type, 2024 (%) [Cell-based Gene Therapy; RNA, Antisense Etc.; Stem Cell & Other Cell Therapy; Other Gene Therapy]
    • Regional Market Summary
      • Table Other Conditions Cell and Gene Therapy Market, by Country/Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
      • Table Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region, Estimated 2024 and Projected 2030 ($ million) [Europe, North America, ROW]
      • Table Other Conditions Cell and Gene Therapy Market Share, by Geographic Region, Estimated 2024 (%) [Europe, North America, ROW]
    • Competitor Summary
  • Cell and Gene Therapy Market Review
    • Market Influences
      • Global Demographics
        • Table Global Population, 1980-2050 (population in millions)
        • Table Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
      • Cost Containment
        • Table Cost Comparisons for Selected Commercialized Cell and Gene Therapies
    • Cell and Gene Therapy and Viral Vector Shortages
    • Global Market Summary
      • Table Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/non-oncology blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Cell, Gene, and RNA Therapy Market Summary, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Cell and Gene Therapy Market, Distribution of Sales by Disease Segment, 2024 [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
    • Cell vs. Gene Therapy Markets
      • Table Cell, Gene, &RNA Therapy Market Summary, by Method, 2024-2030 ($ million)
      • Table Cell, Gene, &RNA Therapy Market, Distribution of Sales, by Method, 2024 (%)
      • Table Cell, Gene, &RNA Therapy Market, Distribution of Sales, by Method, 2029 (%)
    • Regional Market Overview
      • Table Cell, Gene, &RNA Therapy Market Summary by Geographical Region, 2024-2030 ($ million) [Europe, North America, ROW]
    • North America
      • Table Cell, Gene, &RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Cell, Gene, &RNA Therapy Market Summary for United States, by Product Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table U.S. Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Major Cell and Gene Therapy Product Approvals, FDA
    • Europe/European Union
      • Table Cell, Gene, &RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Cell, Gene, &RNA Therapy Market Summary for Europe/European Union, by Disease Area, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Europe Cell and Gene Therapy Market, Distribution by Product Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Major Cell and Gene Therapy Approvals by EMA
    • Other Countries
      • Table Cell, Gene, &RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Cell, Gene, &RNA Therapy Market Summary for Other Countries, by Disease Segment, 2024-2030 ($ million) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table ROW Cell, Gene, &RNA Therapy Market, Distribution by Disease Segment, 2024 (%) [Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other]
      • Table Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
    • Competitor Ranking in Cell and Gene Therapy Markets
      • Table Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
      • Table Estimated Cell and Gene Therapy Sales by Leading Competitors, 2024 Sales ($ million) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
      • Table Cell and Gene Therapy Market Share Estimates by Leading Competitors, 2024 (%) [Alnylam, BMS, Biogen, Janssen, Kite/Gilead, Novartis, Sarepta, Other]
  • Market Participants
    • Leading Influencers
    • AlloSource
      • Table AlloSource Corporate Summary
      • Company Summary
      • Products
    • Alnylam Pharmaceuticals, Inc.
      • Table Alnylam Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • Amgen
      • Table Amgen Corporate Summary
      • Company Summary
      • Products
    • AnGes Inc.
      • Table AnGes Corporate Summary
      • Company Summary
      • Products
    • Anterogen Co Ltd.
      • Table Anterogen Corporate Summary
      • Company Summary
      • Products
    • Atara Biotherapeutics
      • Table Atara Biotherapeutics Corporate Summary
      • Company Summary
      • Products
    • BioCardia
      • Table BioCardia Summary
      • Company Summary
      • Products
      • Projects in the pipeline using the CardiAMP system include:
      • Projects in the pipeline using the CardiALLO system include:
    • Biogen, Inc.
      • Table Biogen Corporate Summary
      • Company Summary
      • Products
    • BioMarin Pharmaceuticals
      • Table BioMarin Pharmaceuticals Corporate Summary
      • Company Summary
      • Products
    • bluebird bio, Inc.
      • Table bluebird bio Corporate Summary
      • Company Summary
      • Products
    • BrainStorm Cell Therapeutics
      • Table BrainStorm Cell Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb Corporate Summary
      • Company Summary
      • Products
    • Candel Therapeutics
      • Table Candel Therapeutics Corporate Summary
      • Company Summary
      • Products
      • In the pipeline, the company offers:
    • Castle Creek Biosciences
      • Table Castle Creek Corporate Summary
      • Company Summary
      • Products
    • Celyad Oncology
      • Table Celyad Oncology Corporate Summary
      • Company Summary
      • Products
    • Cook Myosite, Inc
      • Table Cook Myosite Corporate Summary
      • Company Summary
      • Products
    • Dendreon Pharmaceuticals (Sanpower)
      • Table Dendreon Corporate Summary
      • Company Summary
      • Products
    • Ferring Pharmaceuticals
      • Table FerGene Corporate Summary
      • Company Summary
      • Products
    • Gamida Cell Ltd.
      • Table Gamida Cell Corporate Summary
      • Company Summary
      • Products
    • GenSight Biologics S.A.
      • Table GenSight Biologics Corporate Summary
      • Company Summary
      • Products
    • Gilead Sciences, Inc.
      • Table Gilead Sciences Corporate Summary
      • Company Summary
      • Products
      • Other selected indications in the pipeline include:
    • Gradalis, Inc
      • Table Gradalis Corporate Summary
      • Company Summary
      • Products
    • Helixmith
      • Table Helixmith Corporate Summary
      • Company Summary
      • Products
    • Inovio Pharmaceuticals, Inc.
      • Table Inovio Pharmaceuticals Corporate Summary
      • Company Summary
      • Products in the Pipeline
    • Medeor Therapeutics
      • Table Medeor Therapeutics Corporate Summary
      • Company Summary
      • Products
    • MEDIPOST Co, Ltd.
      • Table MEDIPOST Corporate Summary
      • Company Summary
      • Products
    • MeiraGTx
      • Table MeiraGTx Corporate Summary
      • Company Summary
      • Products
    • Mesoblast Ltd.
      • Table Mesoblast Corporate Summary
      • Company Summary
      • Products
    • Northwest Biotherapeutics, Inc.
      • Table Northwest Biotherapeutics Corporate Summary
      • Company Summary
      • Products
    • Novartis AG
      • Table Novartis Corporate Summary
      • Company Summary
      • Products
      • Other Current Projects
    • NuVasive Biologics
      • Table NuVasive Biologics Corporate Summary
      • Company Summary
      • Products
    • Orchard Therapeutics
      • Table Orchard Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Organogenesis
      • Table Organogenesis Corporate Summary
      • Company Summary
      • Products
    • Orthofix
      • Table Orthofix Corporate Summary
      • Company Summary
      • Products
    • Osiris Therapeutics, Inc. (Smith & Nephew)
      • Table Osiris Corporate Summary
      • Company Summary
      • Products
    • Pharmicell
      • Table Pharmicell Corporate Summary
      • Company Summary
      • Products
    • Pluristem Therapeutics, Inc.
      • Table Pluristem Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Sangamo Therapeutics
      • Table Sangamo Therapeutics Corporate Summary
      • Company Summary
      • Products
    • Sanofi
      • Table Sanofi Corporate Summary
      • Company Summary
    • Sarepta Therapeutics
      • Table Sarepta Corporate Summary
      • Company Summary
      • Products
    • Sotio a.s.
      • Table Sotio Corporate Summary
      • Company Summary
      • Products
    • Spark Therapeutics
      • Table Spark Therapeutics Corporate Summary
      • Company Summary
      • Products
      • Pipeline Projects
    • uniQure N.V.
      • Table uniQure Corporate Summary
      • Company Summary
      • Products
    • Vericel Corporation
      • Table Vericel Corporate Summary
      • Company Summary
      • Products

$8,000

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings